Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments ...

A recent study has found that a class of diabetes drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors may increase ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ...

Both SGLT2 inhibitors and GLP-1s lowered moderate or severe COPD exacerbation risk vs. DPP-4 inhibitors. Weight loss and SGLT2 inhibitors’ glucosuria effect may explain the findings. Sodium ...

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...